789.9000 -11.20 (-1.40%)
NSE Jan 14, 2026 15:31 PM
Volume: 43,944
 

Karvy
Valuation and Risks: We upgrade our revenues by 3.2% / 3.3% for FY21E/FY22E at Rs 52 bn / Rs 56 bn respectively due to upgrade in US, ROW and API business.
Alembic Pharmaceutic.. has an average target of 1028.50 from 4 brokers.
More from Alembic Pharmaceuticals Ltd.
Recommended